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106Extramedullary Relapse of Acute Myelogenous
Leukemia after Allogeneic Hematopoietic
Stem Cell Transplantation: Better Prognosis
Than Systemic Relapse
Melhem Solh,1,2 Todd E. DeFor,3 Daniel J. Weisdorf,1,2 Dan S. Kaufman1,2Allogeneic hematopoietic cell transplantation (HSCT) is considered a curative treatment for acute myelog-
enous leukemia (AML). Extramedullary relapse after HSCT for AML is a rare event and is less well defined
than systemic, hematologic relapse. We retrospectively studied all patients with AML (n5 436) who under-
went HSCTat the University of Minnesota between 1996 and 2008 who developed either a bone marrow
(BM) or extramedullary (EM) relapse, and examined the incidence and risk factors for BM and EM relapse.
Of 128 patients who relapsed post-HSCT, 25 had relapse in EM sites, either isolated (n 5 13) or with con-
current BM relapse (n 5 12). Relapse sites included bone (n 5 1), central nervous system (n 5 6), gastro-
intestinal (n 5 4), lymphatic (n 5 4), skin (n 5 5), genitourinary (n 5 1), pulmonary (n 5 1), and soft tissue
(n 5 3). The time to relapse was longer in the EM sites (median, 328 days vs 168 days). Patients with EM
relapse were more likely to have had preceding acute graft-versus-host disease (GVHD) (77% vs 49%;
P5.03) or chronic GVHD (46% vs 15%; P5.02) comparedwith those with BM relapse. The 6-month survival
postrelapse was significantly better in patients with isolated EM relapse (69%) compared with those with
combined EM and BM relapse (8%) or those with BM relapse alone (27%) (P\.01). Compared with local
therapy alone, systemic therapy yielded better 6-month survival in patients with EM relapse. This study sug-
gests differing pathogenesis of BM relapse versus EM relapse of AML after allogeneic HSCT. GVHD and its
accompanying graft-versus-leukemia effect may better protect BM sites, but patients with EM relapse have
better responses to combined therapy and improved survival compared with those with BM relapse.
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Allogeneic hematopoietic stem cell transplanta-
tion (HSCT) is considered a standard treatment and
potentially curative for a significant subset of patients
with acute myelogenous leukemia (AML) [1]. How-
ever, disease relapse remains the most common cause1Blood and Marrow Transplant Program; 2Divsion of
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6/j.bbmt.2011.05.023of treatment failure post-HSCT [2]. Although the
incidence of leukemia relapse in intermediate and
high-risk patients with AML is reduced after alloge-
neic HSCT compared with conventional consolida-
tion chemotherapy [3-5], a significant number of
extramedullary (EM) relapses have been reported
[6-8]. EM relapse has been reported in diverse sites,
including the brain [9], breast [10], head and neck
[11], gastrointestinal (GI) tract [12], liver [13], uro-
genital tract [12], spinal canal [11], bone [10,12],
skin [14], chest [13], and peritoneum [15]. The median
time from HSCT to EM relapse is longer than that
from HSCT to bone marrow (BM)-only relapse; Lee
et al. [6] reported a median time of 13.5 months
post-HSCT in patients with EM relapse, compared
with 6.1 months in those with BM-only relapse. Al-
though EM relapse remains a rare and devastating
event, little is known about its incidence, biology
(eg, sanctuary sites, uneven graft-vs-leukemia [GVL]
effect) [16,17], risk factors (differing cytogenetic or
morphologic French-American-British [FAB] cate-
gory), treatment, and outcomes. Other reported
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include disease status at HSCT and T cell depletion
of the hematopoietic cell graft [6].
We investigated the incidence of medullary and
EM relapse among 436 consecutive adult and pediatric
patients with AML who underwent allogeneic HSCT
between 1996 and 2008 at the University of Minnesota
to identify any differences between relapse in the BM
and EM sites in terms of risk factors, response to
therapy, and overall outcome.PATIENTS AND METHODS
Study Design and Patient Selection
For this single-institution retrospective cohort
study, we reviewed the University of Minnesota’s
Blood andMarrowTransplant Database to identify pa-
tients with AML who experienced relapse after under-
going allogeneic HSCT between January 1996 and
December 2008. The relapsed patients were divided
into 3 subgroups: isolated BM-only relapse (n 5 103),
EM relapse without concurrent BM relapse (n 5 13),
and EM relapse with concurrent BM relapse (n 5 12).
All patients who experienced EM relapse underwent
a BM biopsy and aspiration for evaluation of the diag-
nosis of EM relapse. EM relapse was confirmed by a
needle or excisional biopsy in all cases and a thorough
workup, including detailed physical examination, tes-
ticular examination, and total body imaging (ie, com-
puted tomography or positron emission tomography
scan) to investigate for other sites of EM leukemia.
Patients’ records were also reviewed for the presence
of EM leukemia before HSCT.
Patients undergoing HSCT while in first complete
remission (CR1) were classified as standard risk; all
other patients were considered high risk. Cytogenetic
risk grouping of the EM relapse patients was assigned
according to Southwest Oncology Group criteria.
AML subtype was assigned according to the FAB
classification system. Systematic and prospectively col-
lected information from the Bone Marrow Transplant
Program Database was supplemented by a review of
medical records. This study was approved by the
University of Minnesota’s Institutional Review Board.Treatment Characteristics
Patients reviewed for this analysis received either
full myeloablative conditioning or reduced-intensity
conditioning (RIC) before undergoing allogeneic
HSCT. Eligibility criteria for RIC included age $55
years for a matched related donor (MRD) transplant
or$45 years for an umbilical cord blood (UCB) trans-
plant, presence of significant comorbidity, and history
of previous HSCT or extensive previous therapy.Most
of the patients who relapsed received a total bodyirradiation (TBI)-based conditioning regimen, with
low-dose TBI (200 cGy) for RIC and high-dose TBI
(1320 cGy) for full myeloablative conditioning. RIC
regimens included busulfan (Bu) 2 mg/kg orally every
12 hours for 4 doses on days 28 and 27, fludarabine
(Flu) 40 mg/m2 i.v. daily from days26 to22, and TBI
200 cGy on day 21 (Bu/Flu/TBI) and cyclophospha-
mide (Cy) 50 mg/kg on day 26 with Flu and TBI as
above, with or without antithymocyte globulin
(ATG) (Cy/Flu/TBI 6 ATG). Full-intensity myeloa-
blative regimens included Cy 60 mg/kg i.v. on days
26 to 25 and TBI 1320 cGy over 8 fractions on days
24 to 21 (Cy/TBI), Bu 16 mg/kg over 16 doses on
days 29 to 26, Cy 50 mg/kg/day on days 25 to 22
(Bu/Cy), and Flu 25 mg/m2 on days 28 to 26 plus
Cy/TBI as above (Flu/Cy/TBI). All patients received
granulocyte-colony stimulating factor 5 mg/kg/day i.v.
starting day on 0 and continuing until the absolute neu-
trophil count was $2500/mL for 2 days.
All patients received graft-versus-host disease
(GVHD) prophylaxis in accordance with University
of Minnesota protocols during the transplantation pe-
riod. Institutional GVHDprophylaxis usually includes
methotrexate plus cyclosporine for full-intensity trans-
plantation and cyclosporine plus mycophenolate for
RIC and UCB transplantation.
Donor Chimerism
Donor chimerism was determined serially on
marrow and/or blood samples obtained after HSCT.
Chimerism analysis was performed using quantitative
polymerase chain reaction of informative polymorphic
variable-number tandem repeat or short tandem re-
peat regions in recipient and donor, as described
previously [18].
Study Definitions and Statistical Analysis
The time to AML relapse was defined as the inter-
val between day 0 of HSCT and the relapse of leuke-
mia. Statistical comparisons of baseline factors across
types of relapse were done using the chi-square or
Fisher exact test for categorical variables and the gen-
eral Wilcoxon test for continuous factors. The cumu-
lative incidence estimates for leukemia relapse were
determined by treating death as a competing risk [19]
and were compared using the log-rank test. Survival
through 6 months postrelapse was estimated using
the Kaplan-Meier method. Cox regression models
were used to investigate the difference in survival
by medullary and EM relapse controlling for con-
founding factors. Factors that were included in the
regression models were donor type (MRD vs mis-
matched related donor; unrelated donor vs UCB), pre-
vious GVHD (both acute and chronic), time from
HSCT to relapse, cytomegalovirus (CMV) serostatus
(negative vs positive), disease status at HSCT (CR1
108 Biol Blood Marrow Transplant 18:106-112, 2012M. Solh et al.vs CR2 vs CR31/relapse), conditioning (myeloabla-
tive vs nonmyeloablative), and age. All factors were
tested for the proportional hazards assumption. All
statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC).
CR was defined as the absence of disease on clini-
cal, radiologic, and pathological evaluation. Partial
remission (PR) was defined as a $50% reduction in
sites of known disease. Failure to achieve PR was de-
fined as persistent disease (PD). Local therapy was
defined as surgical resection and/or local radiation to
the involved area. Patients who received intrathecal
chemotherapy for central nervous system (CNS) leu-
kemia without other systemic therapy were considered
to have received local therapy. Systemic therapy
included donor lymphocyte infusion (DLI), chemo-
therapy, and second HSCT. Combined therapy was
defined as administration of both local and systemic
therapy. Patients were considered to have undergone
surgery as a therapeutic modality only if surgical exci-
sion was done for treatment intention (ie, removal of
a mass) or if an excisional biopsy was obtained in which
the whole lesion was excised, with no positive margins
on pathology.RESULTS
Patient Characteristics
Between 1996 and 2008, 436 adult and pediatric
patients with AML underwent allogeneic HSCT. Of
these 436 patients, 128 experienced relapse; the cumu-
lative incidence of relapse at 5 years was 35% (95%
confidence interval [CI], 30%-40%). Of these, 103
had BM-only relapse, 13 had EM relapse with concur-
rent BM relapse, and 12 had EM relapse without
concurrent BM relapse. Themedian age of the patients
who relapsed was 43 years (range, 1-70 years). The
3 relapse groups did not differ in terms of CMV
donor–recipient serostatus, hematopoietic cell source
(BM, peripheral blood, orUCB), donor source (related
or unrelated), conditioning intensity, and GVHD
prophylaxis. A significantly higher proportion of the
patients in the isolated EM relapse group had previous
grade II-IV acute GVHD (77%), compared with 49%
in BM relapse–only group and 25% in the EM plus
concurrent BM relapse group (P 5 .03). Of the 25
patients with EM relapse, 5 had normal cytogenetics,
3 had favorable cytogenetics, 14 had unfavorable cyto-
genetics, and 3 had undetermined prognostic cytoge-
netics. Patient, disease, and transplant characteristics
are summarized in Table 1.Patients with EM Relapse
Table 2 summarizes the site distribution, treat-
ment, and outcomes for patients with EM relapsewith or without marrow relapse. The CNS, GI tract,
skin, and soft tissue were the most common sites of
EM relapse. Only 5 of the 25 patients with EM re-
lapse had EM leukemia before undergoing HSCT,
with 1 case each involving the skin, CNS, lymph no-
des, soft tissue, and mediastinum. All of these patients
relapsed in the same site as the previous leukemia,
whereas the patient with leukemia cutis before
HSCT had an additional relapse in the CNS post-
HSCT. Among the 6 patients with CNS involvement,
2 had a brain mass, 2 had a spinal mass, and 2 had only
cerebrospinal fluid involvement. In the 4 patients
with GI involvement, sites included the pharynx,
parotid gland, jejunum, and duodenum. Involved
soft tissue sites included breast and labia (n5 1), para-
spinal tissue (n 5 1), and thigh, pelvis, and popliteal
fossa (n 5 1).
Eight patients received local therapy only, includ-
ing local radiation (n 5 5), surgical resection (n 5 2),
and intrathecal chemotherapy (n 5 1). Six patients
received DLI, 3 patients had chemotherapy followed
by a second HSCT, 2 patients received no therapy,
1 patient had withdrawal of immunosuppression, and
the rest received chemotherapy using varying agents
(eg, gemtuzumab ozagamycin, cytarabine, fludarabine,
hydroxyurea). Eight patients experienced a second
relapse after achieving a CR after treatment of the first
relapse. Two patients with concurrent EM and medul-
lary relapse experienced their second relapse in the BM
only. In the 6 patients with isolated EM relapse who
achieved a CR and later relapsed again, the involved
sites were pleura (previous relapse site, small bowel),
humerus, and soft tissue (previous relapse site, parotid
gland), CNS (previous relapse site, CNS), BM (previ-
ous relapse site, CNS), and 2 soft tissue (previous
relapse sites, soft tissue in various locations). Among
the 8 patients who experienced a second relapse, 5
patients received chemotherapy plus DLI as previous
therapy.Survival Postrelapse
The 6-month overall survival (OS) postrelapse was
30% for all 128 patients who relapsed (Table 3). As
shown in Figure 1, patients with isolated EM relapse
had a better 6-month OS (69%; 95% CI, 37%-87%)
compared with patients with BM-only relapse (27%;
95% CI, 19%-36%) and those with EM plus concur-
rent medullary relapse (8%; 95% CI, 1%-31%)
(P\ .01). Patients with chronic GVHD before relapse
had improvedOS after relapse, perhaps due to a persis-
tent (although incomplete) GVL effect. Early onset of
relapse (\6 months post-HSCT) was associated with
poor outcome.
The Cox regression analysis of factors associated
with improved survival for AML relapse post-HSCT
identified the following favorable factors: isolated
Table 1. Demographic Data for Patients with Relapsed AML Post-HSCT (n 5 128)
Factor Marrow Relapse
EM without Concurrent
BM Relapse (n 5 13)
EM with Concurrent
BM Relapse (n 5 12)
Patients with Post-HSCT
Relapse (n 5 128) P Value
Age, years, median (range) 44 (1-70) 27 (1-57) 35 (1-56) 43 (1-70) .20
Time to relapse, days, median (range) 168 (21-2273) 328 (30-2329) 146 (21-813) 168 (21-2329) .42
Male sex 56 (54) 7 (54) 8 (67) 71 .71
AML, n (%) 103 13 12 128 .93
FAB0 5 (5) 1 (8) 1 (8) 7
FAB1 13 (13) 0 1 (8) 14
FAB2 24 (23) 3 (23) 3 (25) 30
FAB3 3 (3) 0 1 (8) 4
FAB4 9 (9) 2 (15) 1 (8) 12
FAB5 9 (9) 4 (31) 2 (17) 15
FAB6 4 (4) 0 1 (8) 5
FAB7 3 (3) 0 0 3
AML not otherwise specified 33 (32) 3 (23) 2 (17) 38
Disease status at HSCT .87
CR1 44 (43) 6 (46) 5 (42) 55
CR2 33 (32) 3 (23) 5 (42) 41
CR3+ 7 (7) 2 (15) 1 (8) 10
Relapse 19 (18) 2 (15) 1 (8) 22
Conditioning intensity .61
Myeloablative 55 (53) 8 (62) 8 (67) 71
RIC 48 (47) 5 (38) 4 (33) 57
Non-TBI 7 (7) 3 (23) 1 (8) 11 .25
Bu/Flu/TBI 7 (7) 1 (8) 0 8
Cy/Flu/TBI ± ATG 45 (44) 4 (31) 6 (50) 55
Cy/TBI 44 (43) 5 (38) 5 (42) 54
Grade II-IV acute GVHD before relapse 50 (49) 10 (77) 3 (25) 63 .03
Chronic GVHD before relapse 15 (15) 6 (46) 2 (17) 23 .02
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GVHD before relapse, and relapse beyond 6 months
post-HSCT. CMV serostatus, disease status at time
of transplantation (CR1, CR2, or CR31/relapse), age,
conditioning regimen, and regimen intensity were
not associated with a change in OS postrelapse.Table 2. Data for Patients with EM Relapse (n 5 25)
Factors
EM without
Concurrent BM,
n (%) (n 5 13)
EM with
Concurrent BM,
n (%) (n 5 12)
Total
(n 5 25) P Value
Relapse site .27
Bone 0 1 (8) 1
CNS 3 (23) 3 (25) 6
GI 3 (23) 1 (8) 4
Genitourinary 0 1 (8) 1
Lymphatic 3 (23) 1 (8) 4
Pulmonary 0 1 (8) 1
Skin 1 (8) 4 (33) 5
Soft tissue 3 (23) 0 3
EM leukemia
before HSCT
5 (38) 3 (25) 8 .47
Type of therapy .94
Combined 3 (23) 2 (17) 5
Local 5 (38) 3 (25) 9
Systemic 4 (31) 6 (50) 9
None 1 (8) 1 (8) 2
Surgical resection 5 (38) 2 (17) 7 .23
Response to
treatment
.05
CR 10 (77) 3 (25) 13
PD 2 (15) 7 (58) 9
PR 1 (8) 2 (17) 3
Second relapse* 6 (46) 2 (17) 8 .11
*Patients who experienced a second relapse after treatment.Survival of Patients with EM Relapse
Table 4 summarizes the survival outcomes of pa-
tients with EM relapse. In univariate analysis, patients
with EM relapse with concurrent BM relapse had sig-
nificantly lower 6-month OS compared with patients
with isolated EM relapse. Patients who received
systemic or combined modality therapy for the EM
relapse had a better OS compared with those treated
with local therapy only.DISCUSSION
Relapse remains the most common cause of treat-
ment failure in patients with AML undergoing alloge-
neic HSCT. The incidence of relapse ranges from
20% to 50% depending on disease characteristics [20],
donor source [21], and conditioning regimen [22]. The
reported incidence of EM relapse after allogeneic
HSCT varies widely. Previous retrospective registry
data reported 20 of 3071 patients with AML with
EM relapse, for an incidence of 0.7% [11].More recent
series based mostly on single institutional reports have
reported higher occurrences of EM relapse, ranging
from 5% to 12% [6,14,23-26]. In our series of 436
patients with AML, the overall relapse rate was 35%,
and the EM relapse rate was 5.7%. EM relapse with
or without BM involvement accounted for 20% of
the overall initial relapses.
Some previous investigators have attributed the
discrepancies in the reported rates of EM relapse
Table 4. OS after HSCT in Patients with EM Relapse
Factors
Number
of Patients
Number
of Deaths
6-Month
Survival
(95% CI), % P Value
Total 25 15 40 (21-58)
Type of relapse <.01
EM without
concurrent BM
13 4 69 (37-87)
EM with
concurrent BM
12 11 8 (1-31)
Relapse site .62
CNS 5 4 20 (1-58)
EM 19 10 47 (24-67)
Testis 1 1
EM leukemia
before HSCT
.26
No 17 9 47 (23-68)
Yes 8 6 25 (4-56)
Therapy <.01
Combined 5 3 40 (5-75)
Local 9 6 33 (8-62)
Systemic 9 4 56 (20-80)
None 2 2
Response to therapy <.01
CR 13 3 77 (44-92)
PD 9 9 0
PR 3 3
Table 3. OS Postrelapse in Patients with Relapse
Factors
Number
of Patients
Number
of Deaths
6-Month
Survival
(95% CI), % P Value
Total 128 90 30 (22-38)
Type of relapse <.01
BM only 103 75 27 (19-36)
EM without
concurrent BM
13 4 69 (37-87)
EM with
concurrent BM
12 11 8 (1-31)
Type of relapse .32
BM 103 75 27 (19-36)
EM 25 15 40 (21-58)
Disease status at HSCT .18
CR1 55 37 33 (21-45)
CR2 41 27 34 (20-49)
CR3+ 10 6 40 (12-67)
Relapse 22 20 9 (2-25)
Donor type .04
MRD 45 30 33 (20-47)
MMRD or URD 13 12 8 (0-29)
UCB 70 48 31 (21-42)
Age, years .77
<40 59 40 32 (21-44)
$40 69 50 28 (18-38)
Acute GVHD
before relapse
.07
No 65 42 35 (24-47)
Yes 63 48 24 (14-35)
Chronic GVHD
before relapse
.04
No 105 78 26 (18-34)
Yes 23 12 48 (27-66)
Time to relapse, months
<6 73 58 21 (12-30) <.01
$6 55 32 42 (29-54)
MMRD indicates mismatched related donor; URD, unrelated donor.
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underreporting in registry data, as well as longer
follow-up in recent series, attributed to longer survival
and generally improved outcomes of HSCT [6]. We
believe that EM may still be underreported, because
asymptomatic EM sites might not be routinely studied
clinically and the full extent can only be known at au-
topsy, which is performed only rarely. It is likely that
occult foci of leukemia exist and are resistant to then
oitr
oporP
evit
al
u
m
uC
Months Post Relapse
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5 6
I
I
I
Extramedullary Alone
Extramedullary + BM
BM
P < 0.01
Figure 1. OS of patients with relapsed AML post-HSCT by type of
relapse. P values are for comparison for any difference between the 3 sur-
vival curves. Looking at the 3 pairwise comparisons, the only 2 that are
significant at the P5.05 level are EM versus BM alone and EM versus BM
plus EM.GVL effect. Such foci are identified clinically either
incidentally or when symptoms arise, but the exact
frequency of this after HSCT is not known.
Various factors have been suggested to contribute
to the risk of EM relapse of AML after allogeneic
HSCT. Simpson et al. [23] reported a higher incidence
of EM relapse after busulfan-containing conditioning
compared with total body irradiation (TBI)-based con-
ditioning, but another study could not confirm this
finding [27].We observed a similar incidence of EM re-
lapse afterTBI-based conditioning and non–TBI-based
conditioning, even after RIC. Other factors previously
suggested to predict EM relapse include AML subtype
(FAB M4 and M5), abnormal karyotype, and disease
status at the time of HSCT [6,7]. However, most of
these reported predictors of EM relapse are from
small retrospective series, and the reproducibility of
these findings is questionable. Our data show a higher
incidence of acute and chronic GVHD in patients
with EM relapse compared with patients with BM
relapse, a finding confirmed in other reports [28].
This suggests that the pathogenesis of EM relapse
might differ from that of the more common BM
relapse, and suggests that immune surveillance through
the GVL effect may be less effective in EM sites.
The timing from HSCT to EM relapse has been
consistently reported to be longer than the time from
HSCT to BM relapse. We and others have reported
a median time to EM relapse of 11-13 months, com-
pared with 3-6 months for BM relapse [6,16,25,
27,28]. Importantly, censoring of surveillance may
accompany a BM relapse that might subsequently
overlook or preemptively treat an unrecognized EM
Biol Blood Marrow Transplant 18:106-112, 2012 111Extramedullary Relapse of AML after Allogeneic HSCTrelapse. In addition, differing expression of adhesion
molecules (e.g. CD561 cells) on surviving leukemic
cells might facilitate adherence to dermal fibroblasts
and thus to sites of isolated EM relapse [29,30]. In
addition, EM sites might serve as sanctuary havens for
the dormant leukemic clone after HSCT. These
sanctuary sites, protected from chemotherapy or
immune responses, might give the leukemic cells
an opportunity for progressive overgrowth [16,31].
Cytotoxic CD81 T cells are the main mediators of the
GVL effect and are highly more concentrated in the
BM compared with the peripheral tissues [32]. Homing
of T cells is regulated by a host of cell surface molecules
(eg, selectins) that direct T cells to specific sites.
Thus, relapse in EM sites may occur in part because
such sites are not well protected by the T cells [33].
The treatment of EM relapse remains a challenge,
given the lack of standardized strategies for manage-
ment. Historically, treatment has consisted of local
therapy, such as surgical excision and/or radiation,
and systemic therapy including DLI, second HSCT,
and/or chemotherapy. These modalities can be used
individually or in combination. Most patients with
EM relapse develop BM disease without systemic
treatment. This argues for providing systemic therapy
for all such patients [7,11,34], a longstanding principle
of management in intensification strategies for
acute lymphoblastic leukemia. Isolated EM relapse is
associated with better survival than BM relapse when
aggressive treatment is provided [28].
In conclusion, our study demonstrates that isolated
EM relapse of AML after allogeneic HSCT is rela-
tively common. EM relapse occurs later than systemic
relapse, and EM relapse without concurrent BM in-
volvement is associated with better prognosis. EM
relapse is more common in patients with GVHD, sug-
gesting that the GVL effect might be less protective in
these EM sites. Additional larger studies are needed to
define risk factors and prognostic indicators and to
establish treatment guidelines.ACKNOWLEDGMENTS
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